19,138 Shares in Abbott Laboratories (NYSE:ABT) Bought by Crowley Wealth Management Inc.

Crowley Wealth Management Inc. acquired a new stake in Abbott Laboratories (NYSE:ABT - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 19,138 shares of the healthcare product maker's stock, valued at approximately $2,165,000. Abbott Laboratories makes up approximately 1.9% of Crowley Wealth Management Inc.'s portfolio, making the stock its 16th biggest holding.

Other institutional investors also recently modified their holdings of the company. Noble Wealth Management PBC bought a new stake in shares of Abbott Laboratories during the fourth quarter worth $26,000. NewSquare Capital LLC lifted its position in Abbott Laboratories by 78.4% during the 4th quarter. NewSquare Capital LLC now owns 239 shares of the healthcare product maker's stock valued at $27,000 after purchasing an additional 105 shares during the period. Rialto Wealth Management LLC bought a new position in shares of Abbott Laboratories in the 4th quarter valued at about $29,000. Wingate Wealth Advisors Inc. bought a new stake in shares of Abbott Laboratories during the fourth quarter worth approximately $34,000. Finally, Newbridge Financial Services Group Inc. acquired a new position in Abbott Laboratories in the fourth quarter valued at approximately $37,000. 75.18% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently weighed in on ABT. The Goldman Sachs Group increased their price target on Abbott Laboratories from $138.00 to $154.00 and gave the company a "buy" rating in a research note on Tuesday, March 4th. Stifel Nicolaus raised their price objective on Abbott Laboratories from $130.00 to $135.00 and gave the stock a "buy" rating in a research note on Thursday, January 23rd. Evercore ISI increased their price target on Abbott Laboratories to $136.00 and gave the stock a "buy" rating in a report on Thursday, January 2nd. Wells Fargo & Company boosted their target price on Abbott Laboratories from $133.00 to $136.00 and gave the company an "overweight" rating in a research note on Thursday, January 23rd. Finally, StockNews.com cut shares of Abbott Laboratories from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, February 12th. Four analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $137.94.

Remove Ads

Abbott Laboratories Stock Performance

Shares of NYSE ABT traded up $3.11 during trading hours on Thursday, reaching $129.72. 940,777 shares of the stock were exchanged, compared to its average volume of 6,748,728. The stock's fifty day simple moving average is $129.35 and its 200 day simple moving average is $120.16. The firm has a market capitalization of $224.97 billion, a price-to-earnings ratio of 16.96, a P/E/G ratio of 2.52 and a beta of 0.70. Abbott Laboratories has a 52 week low of $99.71 and a 52 week high of $141.23. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.14 and a current ratio of 1.60.

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings results on Wednesday, January 22nd. The healthcare product maker reported $1.34 EPS for the quarter, hitting analysts' consensus estimates of $1.34. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The business had revenue of $10.97 billion for the quarter, compared to analyst estimates of $11.03 billion. During the same period last year, the firm earned $1.19 earnings per share. Abbott Laboratories's revenue for the quarter was up 7.2% compared to the same quarter last year. Sell-side analysts predict that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be paid a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a yield of 1.82%. The ex-dividend date of this dividend is Tuesday, April 15th. Abbott Laboratories's dividend payout ratio (DPR) is presently 30.85%.

Insiders Place Their Bets

In related news, EVP Lisa D. Earnhardt sold 91,167 shares of the company's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $133.82, for a total transaction of $12,199,967.94. Following the completion of the sale, the executive vice president now directly owns 71,928 shares in the company, valued at $9,625,404.96. This represents a 55.90 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Eric Shroff sold 562 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $138.17, for a total transaction of $77,651.54. Following the completion of the transaction, the senior vice president now directly owns 31,970 shares of the company's stock, valued at $4,417,294.90. This trade represents a 1.73 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 116,449 shares of company stock worth $15,463,316 over the last ninety days. Corporate insiders own 0.46% of the company's stock.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.